Kraig Biocraft Laboratories Inc (KBLB)

[Bucks4Buckeyes]

Possibly, but that is a little bit of a stretch, I think. Twice the 'commercialization' was mentioned and then the status of second generation developments was labelled as 'additionally' - so the priority of the CC (as stated by the company) is PRIMARILY a commercialization update.

Anything less will be unacceptable, to me.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (PINKSHEETS: KBLB) announces that the Company will host an upcoming conference call to discuss product, scientific and commercialization developments. The conference call schedule is being worked around the holiday and is tentatively scheduled for the first or second week of January, and will feature the Company's founder and CEO, Kim Thompson.

The Company recently announced that it has succeeded in creating seven new strains of genetically modified silkworm using zinc finger nuclease technology. Those new transgenics are expected to become the basis for the Company's new platform technology.

"The pace of discovery and invention in the laboratory has been accelerating due to our successful integration of zinc finger technologies," said Thompson.

"We are eager to update our textile and business community as to these developments and what they mean for our commercialization pipeline. We will also discuss significant commercialization and corporate developments, and strategies for the coming year."

Additional topics include the recent breakthrough with zinc finger nuclease technology, as well as the status of other second generation spider-silk developments.

The Company will release the conference call details, including time, date and medium, in an upcoming Company release.

Shareholders are invited to submit questions to [e-mail].

All The Best